Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S095029 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT05162755Phase 1Completed
- Sponsor
- Servier
- Start
- Oct 2021
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of sym021 in solid tumor (2 arms), sponsored by Servier. Primary endpoints: Adverse Events up to 2 years and Dose Limiting Toxicities at 28 days. Started Oct 2021; status: completed.
02
Drugs
sym021
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05162755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162755.